BACKGROUND: Recent reports suggest that off-label use of drug-eluting stents is associated with an increased incidence of adverse events. Whether the use of bare-metal stents would yield different results is unknown. METHODS: We analyzed data from 6551 patients in the National Heart, Lung, and Blood Institute Dynamic Registry according to whether they were treated with drug-eluting stents or bare-metal stents and whether use was standard or off-label. Patients were followed for 1 year for the occurrence of cardiovascular events and death. Off-label use was defined as use in restenotic lesions, lesions in a bypass graft, left main coronary artery disease, or ostial, bifurcated, or totally occluded lesions, as well as use in patients with a reference-vessel diameter of less than 2.5 mm or greater than 3.75 mm or a lesion length of more than 30 mm. RESULTS: Off-label use occurred in 54.7% of all patients with bare-metal stents and 48.7% of patients with drug-eluting stents. As compared with patients with bare-metal stents, patients with drug-eluting stents had a higher prevalence of diabetes, hypertension, renal disease, previous percutaneous coronary intervention and coronary-artery bypass grafting, and multivessel coronary artery disease. One year after intervention, however, there were no significant differences in the adjusted risk of death or myocardial infarction in patients with drug-eluting stents as compared with those with bare-metal stents, whereas the risk of repeat revascularization was significantly lower among patients with drug-eluting stents. CONCLUSIONS: Among patients with off-label indications, the use of drug-eluting stents was not associated with an increased risk of death or myocardial infarction but was associated with a lower rate of repeat revascularization at 1 year, as compared with bare-metal stents. These findings support the use of drug-eluting stents for off-label indications. Copyright 2008 Massachusetts Medical Society.
BACKGROUND: Recent reports suggest that off-label use of drug-eluting stents is associated with an increased incidence of adverse events. Whether the use of bare-metal stents would yield different results is unknown. METHODS: We analyzed data from 6551 patients in the National Heart, Lung, and Blood Institute Dynamic Registry according to whether they were treated with drug-eluting stents or bare-metal stents and whether use was standard or off-label. Patients were followed for 1 year for the occurrence of cardiovascular events and death. Off-label use was defined as use in restenotic lesions, lesions in a bypass graft, left main coronary artery disease, or ostial, bifurcated, or totally occluded lesions, as well as use in patients with a reference-vessel diameter of less than 2.5 mm or greater than 3.75 mm or a lesion length of more than 30 mm. RESULTS: Off-label use occurred in 54.7% of all patients with bare-metal stents and 48.7% of patients with drug-eluting stents. As compared with patients with bare-metal stents, patients with drug-eluting stents had a higher prevalence of diabetes, hypertension, renal disease, previous percutaneous coronary intervention and coronary-artery bypass grafting, and multivessel coronary artery disease. One year after intervention, however, there were no significant differences in the adjusted risk of death or myocardial infarction in patients with drug-eluting stents as compared with those with bare-metal stents, whereas the risk of repeat revascularization was significantly lower among patients with drug-eluting stents. CONCLUSIONS: Among patients with off-label indications, the use of drug-eluting stents was not associated with an increased risk of death or myocardial infarction but was associated with a lower rate of repeat revascularization at 1 year, as compared with bare-metal stents. These findings support the use of drug-eluting stents for off-label indications. Copyright 2008 Massachusetts Medical Society.
Authors: Laura Mauri; Wen-hua Hsieh; Joseph M Massaro; Kalon K L Ho; Ralph D'Agostino; Donald E Cutlip Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Keith D Dawkins; Eberhard Grube; Giulio Guagliumi; Adrian P Banning; Krzysztof Zmudka; Antonio Colombo; Leif Thuesen; Karl Hauptman; Jean Marco; William Wijns; Jeffrey J Popma; Joerg Koglin; Mary E Russell Journal: Circulation Date: 2005-11-14 Impact factor: 29.690
Authors: Gregg W Stone; Stephen G Ellis; Louis Cannon; J Tift Mann; Joel D Greenberg; Douglas Spriggs; Charles D O'Shaughnessy; Samuel DeMaio; Patrick Hall; Jeffrey J Popma; Joerg Koglin; Mary E Russell Journal: JAMA Date: 2005-09-14 Impact factor: 56.272
Authors: Bo Lagerqvist; Stefan K James; Ulf Stenestrand; Johan Lindbäck; Tage Nilsson; Lars Wallentin Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Gregg W Stone; Jeffrey W Moses; Stephen G Ellis; Joachim Schofer; Keith D Dawkins; Marie-Claude Morice; Antonio Colombo; Erick Schampaert; Eberhard Grube; Ajay J Kirtane; Donald E Cutlip; Martin Fahy; Stuart J Pocock; Roxana Mehran; Martin B Leon Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Giora Weisz; Martin B Leon; David R Holmes; Dean J Kereiakes; Mel R Clark; Barry M Cohen; Stephen G Ellis; Patrick Coleman; Carolyn Hill; Chunxue Shi; Donald E Cutlip; Richard E Kuntz; Jeffrey W Moses Journal: J Am Coll Cardiol Date: 2006-03-20 Impact factor: 24.094
Authors: Joachim Schofer; Michael Schlüter; Anthony H Gershlick; William Wijns; Eulogio Garcia; Erick Schampaert; Günter Breithardt Journal: Lancet Date: 2003-10-04 Impact factor: 79.321
Authors: Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell Journal: N Engl J Med Date: 2004-01-15 Impact factor: 91.245
Authors: Erick Schampaert; Eric A Cohen; Michael Schlüter; François Reeves; Mouhieddin Traboulsi; Lawrence M Title; Richard E Kuntz; Jeffrey J Popma Journal: J Am Coll Cardiol Date: 2004-03-17 Impact factor: 24.094
Authors: Zhi-Jiang Zhang; Oscar C Marroquin; Roslyn A Stone; Joel L Weissfeld; Suresh R Mulukutla; Faith Selzer; Kevin E Kip Journal: Am Heart J Date: 2010-11 Impact factor: 4.749
Authors: Suresh R Mulukutla; Helen A Vlachos; Oscar C Marroquin; Faith Selzer; Elizabeth M Holper; J Dawn Abbott; Warren K Laskey; David O Williams; Conrad Smith; William D Anderson; Joon S Lee; Vankeepuram Srinivas; Sheryl F Kelsey; Kevin E Kip Journal: JACC Cardiovasc Interv Date: 2008-04 Impact factor: 11.195
Authors: Suresh R Mulukutla; Oscar C Marroquin; Helen A Vlachos; Faith Selzer; Catalin Toma; Kevin E Kip; J Dawn Abbott; Elizabeth Holper; Joon S Lee; Sameer Khandhar; Michael Kutcher; Sheryl Kelsey; Conrad Smith; David Faxon; David O Williams Journal: Am J Cardiol Date: 2012-12-01 Impact factor: 2.778